Abstract 141: Door-to-Puncture: A Practical Metric for Capturing and Enhancing System Processes Associated With Endovascular Stroke Care, Preliminary Results From the Rapid Reperfusion Registry
Background/Purpose: In 2011, the Brain Attack Coalition proposed an “Arrival-to-Treatment” of two hours as a benchmark for ischemic stroke patients undergoing intra-arterial therapy (IAT). We designed the Rapid Reperfusion Registry to capture the percentage of stroke patients being treated within the targeted time frame, and to assess the clinical impact of the metric on patient outcomes.
Methods: This is a retrospective analysis of consecutive anterior circulation patients treated with IAT within 9 hours of symptom onset from nine institutions. Data was collected from December 31, 2011 to Dec 31, 2012 at two centers and from July 1, 2012 to December 31, 2012 at seven centers. Short “Door to Puncture” (D2P) time was hypothesized to be associated with good patient outcomes (90 day modified Rankin Scale score of 0-2), which was confirmed on logistic regression modeling.
Results: A total of 478 patients were analyzed, with a mean age of 68±14 years and median NIHSS of 18 (IQR 14-21). The median times for IAT delivery were 234 minutes (IQR 164-304) from ‘last known normal to puncture’ (LKN-to-GP) and 111 minutes (IQR 65-173) from D2P. The overall good outcome rate was 39.7% for the entire cohort. In a multivariable model adjusting for age, NIHSS, hypertension, diabetes, reperfusion status, and symptomatic hemorrhage, both short LKN-to-GP (OR 0.996; 95%CI [0.994-0.998]; p<0.001) and short D2P times (OR 0.993, 95%CI [0.990-0.996]; p<0.001) were associated with good outcomes. Only 52% of all patients in the registry achieved the targeted D2P time of two hours.
Conclusions: The pre-treatment time interval of D2P presents a clinically relevant time frame by which system processes can be targeted on a national level to streamline the delivery of IAT care. At present, there is much opportunity to reduce delays within this narrow time window, thus, providing an opportunity to enhance patient outcomes.
Author Disclosures: C.J. Sun: None. M. Ribo: Research Grant; Modest; Recipient of a grant from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad. M. Goyal: Speakers' Bureau; Modest; Covidien EV3. Research Grant; Significant; Institutional grant for ESCAPE trial from Covidien EV3. Consultant/Advisory Board; Significant; Covidien EV3 for help with design and execution of SWIFT PRIME. A. Yoo: Research Grant; Modest; Receives research funding from the National Institutes of Health (NIH), Penumbra Inc, and Remedy Pharmaceuticals. T. Jovin: Consultant/Advisory Board; Modest; Silk Road Medical. C. Cronin: None. O. Zaidat: Honoraria; Modest; penumbra, stryker, microvention, EV3, codman. Consultant/Advisory Board; Modest; penumbra, stryker, microvention, EV3, codman. R. Nogueira: Consultant/Advisory Board; Modest; Scientific advisory board for Stryker Neurovascular, Covidien, CoAxia. He also serves on the Data Safety Monitoring Board for Rapid Medical and Imaging Core Lab for Covidien and Reverse Medical. Other; Modest; Editor of Interventional Neurology. T. Nguyen: None. S. Hussain: None. B. Menon: None. B. Mehta: None. G. Jindal: None. A. Horev: None. A. Norbash: None. T. Leslie-Mazwi: None. R. Gupta: Consultant/Advisory Board; Modest; scientific advisory board for Stryker Neurovascular, Covidien, CoAxia. He is also a member of the Data Safety Monitoring Board for Reverse Medical and Rapid Medical. Other; Modest; Associate Editor for the Journal of Neuroimaging, and Associate Editor for Interventional Neurology.
- © 2014 by American Heart Association, Inc.